Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | PKM | P14618 | 9/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16409837 | 0.82 | HDAC3 (0.64) | LMNACYP3A4CYP2C9HTTSMN1; SMN2 | |
| SCHEMBL4896390 | 0.80 | PKM (0.57) | LMNAPKMCYP3A4CYP2C9HTT | |
| SCHEMBL15711215 | 0.80 | CA12 (0.53) | LMNAPKMHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL10154007 | 0.79 | PKM (0.67) | PKMALDH1A1L3MBTL1 | |
| SCHEMBL22735897 | 0.77 | LMNA (0.62) | LMNACYP3A4CYP2C9HTTALDH1A1 | |
| SCHEMBL22735649 | 0.77 | LMNA (0.64) | LMNACYP3A4CYP2C9HTTSMN1; SMN2 | |
| SCHEMBL2593253 | 0.77 | PKM (0.60) | LMNAPKMCYP3A4SMN1; SMN2 | |
| SCHEMBL2206236 | 0.75 | CA12 (0.53) | LMNAPKMCYP3A4CYP2C9HTT | |
| SCHEMBL4712443 | 0.74 | PKM (0.57) | PKMHTTALDH1A1L3MBTL1 | |
| SCHEMBL14089190 | 0.74 | PKM (0.60) | PKMCYP3A4ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369742-A1 | METHODS OF TREATING THROMBOSIS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2021-12-02 | — | — | US | disclosed |
| US-9708267-B2 | Activators of human pyruvate kinase | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-07-18 | — | — | US | disclosed |
| US-20150183744-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | US HEALTH (US) | 2015-07-02 | — | — | US | disclosed |
| US-20130109672-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE (US) | 2013-05-02 | — | — | US | disclosed |
| EP-2563761-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011137089-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183744-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | PDK2, PDK1, PDK3 | LMNA 500/4885PKM 6/4885CYP3A4 2492/4885 |
| US-20130109672-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | PDK2, PDK1, PKLR | LMNA 462/4885PKM 6/4885CYP3A4 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.